Target intelligence / Profile preview

NADH:ubiquinone oxidoreductase subunit A2 (NDUFA2)

Target
NDUFA2
Molecular classification
Enzyme, Mitochondrial Complex I subunit
01

Overview

NADH:ubiquinone oxidoreductase subunit A2 (NDUFA2) is an accessory subunit of mitochondrial Complex I, the first and largest enzyme complex of the electron transport chain situated in the mitochondrial inner membrane. The protein consists of 99 amino acids and contributes to the hydrophobic fraction that helps anchor Complex I to the membrane and supports assembly and regulation. While NDUFA2 is not involved in the catalytic process of electron transfer, it is critical for proper complex formation and function. Mutations in the NDUFA2 gene cause mitochondrial Complex I deficiency and Leigh syndrome, a progressive neurodegenerative disorder characterized by early-onset neurological decline. There are no known drugs that selectively target NDUFA2, but pharmacological inhibition of Complex I indirectly affects its function in the electron transport chain.

Other names
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2Complex I B8 subunitB8CI-B8Complex I-B8NADH-ubiquinone oxidoreductase B8 subunitMC1DN13CD14CIB8
02

Mechanism of action

Inhibition of electron transfer through mitochondrial Complex I; Disruption of proton pumping and mitochondrial membrane potential via Complex I blockade (generic for Complex I inhibitors like rotenone; not specific for NDUFA2 subunit)

03

Biological functions

Electron transportRedox regulationAssembly and structural stabilization of mitochondrial Complex IRespiration
04

Disease associations

Neurodegenerative disease (Leigh syndrome)Mitochondrial Complex I deficiencyLeukoencephalopathy (related forms per gene databases)
05

Safety considerations

Loss of NDUFA2 function leads to severe mitochondrial dysfunction, neurological deterioration, and early-onset neurodegenerative disease
06

Interacting drugs

rotenone
07

Biomarkers

NDUFA2 mutation status for diagnosis of Leigh syndromeComplex I activity assays in mitochondrial disease evaluation

Beyond the preview

Go deeper on NADH:ubiquinone oxidoreductase subunit A2 (NDUFA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NADH:ubiquinone oxidoreductase subunit A2 (NDUFA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call